Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain
March 30 2022 - 08:30AM
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to
treat disorders of the central nervous system (the "Company" or
"SciSparc"), today announced the appointment of Professor Avi
Schroeder as a member of the Company's Scientific Advisory Board
(SAB). As a member of the SAB, Prof. Schroeder will support the
development of the Company's top-tier, proprietary, investigational
drug candidate SCI-160 program for the treatment of pain. Prof.
Schroeder will advise the Company on the formulation development of
SCI-160 to enhance the proprietary synthetic CB2 receptor agonist’s
biological effect and extend effect duration.
The Company previously achieved positive results
in a series of pre-clinical trials in which the efficacy and safety
of SCI-160 was demonstrated in both acute and chronic pain.
Prof. Schroeder is the head of the Targeted Drug
Delivery and Personalized Medicine Group, at the Technion, Israel
Institute of Technology and has translational experience with the
development of liposome-based clinical systems. He is the author of
scientific papers in the field of nanotechnology and medicine and
is the inventor on 14 patents, and recipient of 20 national and
international innovation awards. Prof. Schroeder is a scientific
entrepreneur, starting five successful Technion spin-outs. Prof.
Schroeder received three degrees in Chemical Engineering from the
Ben-Gurion University of the Negev and his postdoctoral training
took place at MIT.
Dr. Adi Zuloff-Shani, SciSparc's Chief
Technologies Officer, commented, "As we continue to make progress
in our innovative program to treat pain, utilizing our non-opioid
analgesic pain management solution, SCI-160, reinforcing our SAB is
essential. Our plans are to commence the Pre-IND process further
this year, followed by an FDA Investigational New Drug (IND) Phase
I study application for our treatment for pain. We welcome Prof.
Schroeder and the great contribution he will bring to our SAB, that
already includes a diverse list of renowned researchers, physicians
and experts advising the company."
The Company’s top-tier, investigational drug
candidate SCI-160 for pain is an innovative and proprietary,
non-opioid, CB2 Receptor (CB2R) agonist formulation intended for
the treatment of pain. This specific CB2R agonist was synthesized
by Professor Raphael Mechoulam, Ph.D., Chairman of SciSparc’s SAB.
CB2 Receptor specific agonists have been found to be involved in
mediating analgesic effects in the peripheral nervous system,
without significant side effects, and CB2R agonists do not cause
the undesirable cannabis psycho-activity effect. The therapeutic
effects and potency have been successfully assessed in animal
models.
About SciSparc
(NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. Our focus is on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or
non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of
Tourette syndrome, for the treatment of Alzheimer's disease and
agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of autism spectrum disorder and status epilepticus.
Forward-Looking Statements:
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. For example, SciSparc is using
forward-looking statements when it discusses appointment of a
professional expert to support the Company's SCI-160 program for
the treatment of pain and the Company's intention to file an IND
phase I study application. Historic results of scientific research
and clinical and preclinical trials do not guarantee that the
conclusions of future research or trials will suggest identical or
even similar conclusions. Because such statements deal with future
events and are based on SciSparc's current expectations, they are
subject to various risks and uncertainties and actual results,
performance or achievements of SciSparc could differ materially
from those described in or implied by the statements in this press
release. The forward-looking statements contained or implied in
this press release are subject to other risks and uncertainties,
including those discussed under the heading "Risk Factors" in
SciSparc's Annual Report on Form 20-F filed with the SEC
on March 30, 2021, and in subsequent filings with the U.S.
Securities and Exchange Commission. Except as otherwise required by
law, SciSparc disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date they were made, whether as a result of new information, future
events or circumstances or otherwise.
Investor Contact:IR@scisparc.com Tel:
+972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Feb 2024 to Mar 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Mar 2023 to Mar 2024